国际湿疹理事会关于特应性皮炎低疾病活动度与缓解的共识定义
国际湿疹理事会通过改良德尔菲法制定特应性皮炎低疾病活动度、极低疾病活动度、用药中完全控制和停药后缓解的共识定义,以统一试验设计和临床评估。
要点
- 低疾病活动度定义为vIGA-AD=2或EASI≤7且PP-NRS≤4。
- 极低疾病活动度定义为vIGA-AD=0/1或EASI≤3且PP-NRS=0/1。
- 用药中完全控制需vIGA-AD=0或EASI=0且PP-NRS=0/1持续≥6个月。
核心结论
- 建立全球认可的专家共识框架,定义特应性皮炎低疾病活动度、极低疾病活动度、用药中完全控制和停药后缓解。
研究设计与样本
- 国际湿疹理事会指导委员会进行目标系统性文献综述,检索PubMed 2004年1月1日至2024年12月31日研究。
- 采用牛津循证医学中心标准评价证据,并进行3轮改良德尔菲法(2025年1月至7月)。
- 预设共识标准:≥70%同意为共识,60%-69%为近共识,<60%为非共识。
主要发现
- 151名专家受邀,第1轮61人(40%)、第2轮37人(25%)、第3轮103人(68%)完成。
- 受访者全球分布:北美59人(29%)、欧洲47人(23%)、亚太60人(30%)、拉丁美洲27人(13%)、中东和非洲7人(3%)。
- 43名专家(74%)在初始调查中支持将临床医生报告体征和患者报告症状作为缓解互补组分的模块化框架。
关键数值与推荐
- 低疾病活动度:vIGA-AD=2或EASI≤7且PP-NRS≤4。
- 极低疾病活动度:vIGA-AD=0/1或EASI≤3且PP-NRS=0/1。
- 用药中完全控制:vIGA-AD=0或EASI=0且PP-NRS=0/1持续≥6个月(排除仅使用非药物保湿剂)。
- 停药后缓解:停药后vIGA-AD=0或EASI=0且PP-NRS=0/1维持≥12个月。
临床怎么用
- 提供标准化定义用于临床试验设计、监管评估和纵向比较效果研究。
- 促进特应性皮炎达标治疗策略的循证实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Advances in targeted therapeutics have made substantial response states in atopic dermatitis (AD) increasingly attainable. However, the field lacks standardized, internationally endorsed definitions of low disease activity (LDA), very low disease activity (vLDA), and remission to benchmark treatment response, support regulatory clarity, and enable consistent cross-trial comparisons. OBJECTIVE: To develop consensus-based definitions of LDA, vLDA, and remission in AD that accommodate regional regulatory frameworks and to refine associated terminology for clinical and research use. EVIDENCE REVIEW: A steering committee from the International Eczema Council (IEC) conducted a targeted systematic literature review. PubMed was searched in July 2024 for studies from January 1, 2004, through December 31, 2024, using combinations of terms related to atopic dermatitis, clinician-reported outcomes, patient-reported outcomes, disease control states, pruritus measures, and disease activity constructs. Evidence was appraised using the Oxford Centre for Evidence-Based Medicine criteria. Key conceptual domains were identified to inform a 3-round sequential modified Delphi process conducted from January to July 2025. Panelists (current IEC members with recognized AD expertise) iteratively reviewed feedback, refined thresholds, and provided qualitative rationale. Predefined criteria distinguished consensus (≥70% agreement), near consensus (60%-69%), and nonconsensus (<60%), guiding which cutoffs were adopted, revised, or excluded. FINDINGS: Of the 151 experts invited, 61 (40%) completed round 1, 37 (25%) completed round 2, and 103 (68%) completed round 3. Responses from participants were globally distributed (North America: 59 [29%]; Europe: 47 [23%]; Asia-Pacific: 60 [30%]; Latin America 27 [13%]; Middle East and Africa: 7 [3%]), including 131 clinician-researchers (66%), 59 clinicians (30%), and 9 researchers (5%); 17 respondents (8%) self-identified as individuals with lived AD experience and/or patient advocacy representatives. A total of 43 panelists (74%) endorsed a modular framework that stratifies clinician-reported signs and patient-reported symptoms as complementary components of remission (eg, remission [signs], remission [symptoms], remission [overall]) in the initial survey. Final consensus definitions included LDA (validated Investigator Global Assessment for Atopic Dermatitis [vIGA] = 2 or Eczema Area and Severity Index [EASI] ≤ 7 plus Peak Pruritus Numerical Rating Scale [PP-NRS] ≤ 4), vLDA (vIGA-AD = 0/1 or EASI ≤ 3 plus PP-NRS = 0/1), on-drug complete control (ie, complete control while taking AD-related medications, excluding only nonmedicated moisturizers/emollients, defined as vIGA-AD = 0 or EASI = 0 plus PP-NRS = 0/1 for ≥6 months), and off-drug remission (ie, remission after stopping treatment, defined as vIGA-AD = 0 or EASI = 0 for plus PP-NRS = 0/1 maintained for ≥12 months after treatment). CONCLUSIONS AND RELEVANCE: This modified Delphi initiative establishes a globally endorsed, expert-derived framework defining LDA, vLDA, on-drug complete control, and off-drug remission in AD. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. By promoting consistent assessment of disease control across studies, this framework advances the field toward evidence-based, treat-to-target AD strategies.
引用
- Merola JF, Childs BA, Bartley BR, et al. International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement. JAMA Dermatol. 2026. PMID: 41984444. doi:10.1001/jamadermatol.2026.0662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。